The leading DPP-4 inhibitor market worth of KRW 260 billion has been fueled again
The DPP-4 inhibitor-type diabetes treatment market has been fueled again.
Although 6 products have been competing in the market, Handok, which has shown its capacity in the diabetes market, also, entered the market and started to actively promote ‘Tenelia(generic name: teneligliptin).’
The DPP-...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
